KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Depreciation & Amortization (2016 - 2025)

Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization history spans 17 years, with the latest figure at $4.7 billion for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 7.19% year-over-year to $4.7 billion, compared with a TTM value of $4.7 billion through Dec 2025, up 7.19%, and an annual FY2025 reading of $4.7 billion, up 7.19% over the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $4.7 billion at Teva Pharmaceutical Industries, up from $4.4 billion in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $5.6 billion in Q4 2023, with the low at $4.4 billion in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $5.1 billion, with a median of $5.2 billion recorded in 2021.
  • Year-over-year, Accumulated Depreciation & Amortization decreased 21.77% in 2024 and then increased 7.19% in 2025.
  • Tracing TEVA's Accumulated Depreciation & Amortization over 5 years: stood at $5.2 billion in 2021, then grew by 5.29% to $5.5 billion in 2022, then increased by 2.16% to $5.6 billion in 2023, then fell by 21.77% to $4.4 billion in 2024, then increased by 7.19% to $4.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Accumulated Depreciation & Amortization are $4.7 billion (Q4 2025), $4.4 billion (Q4 2024), and $5.6 billion (Q4 2023).